428854-24-4

Usage

Uses

Used in Pharmaceutical Industry:
2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidine-4,5,6-triamine is used as a therapeutic agent for the treatment of pulmonary hypertension. Its application is based on its ability to stimulate soluble guanylate cyclase, which plays a crucial role in regulating vascular tone and blood pressure. By enhancing the production of cyclic guanosine monophosphate (cGMP), 2-[1-(2-Fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyriMidine-4,5,6-triaMine helps to relax smooth muscle cells in blood vessels, leading to vasodilation and reduced pulmonary arterial pressure.

Upstream product

• 62009-47-6 2-aminopropanediamide 
• 256499-19-1 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboximidamide hydrochloride 
• 428854-23-3 C₂₃H₁₈FN₉ 
• 256376-59-7 ethyl 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxylate 
• 256376-68-8 please input 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-formamidine 
• 304874-06-4 methyl 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carbimidate 
• 256376-62-2 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carboxamide 
• 256504-39-9 ethyl 5-amino-1-(2-fluorobenzyl)-1H-pyrazole-3-carboxylate 
• 256376-65-5 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-carbonitrile 
• 51859-98-4 (2-fluorobenzyl)hydrazine 
• 370879-49-5 2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-5-[(E)-phenyldiazen-1-yl]pyrimidine-4,6-diamine 

Downstream Products

• 625115-55-1 Riociguat 
• 457914-32-8 2-({4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}amino)ethanol 
• 370879-47-3 N'-[2-(tert-butyl-dimethyl-silanyloxy)-ethyl]-2-[1-(2-fluoro-benzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-pyrimidine-4,5,6-triamine 
• 1702271-98-4 2-{1-[(2-fluorophenyl)methyl]-1H-pyrazolo[3,4-b]pyridin-3-yl}-5-N-methylpyrimidine-4,5,6-triamine 
• 1361569-05-2 6-amino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-7,9-dihydro-8H-purine-8-thione 
• 1361569-10-9 6-amino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-7,9-dihydro-8H-purin-8-one 
• 1361570-55-9 2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-N⁵-isopropylpyrimidine-4,5,6-triamine 
• 1361569-35-8 2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-9H-purin-6-amine 
• 1361570-28-6 2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-N-5-(2,2,2-trifluoroethyl)pyrimidine-4,5,6-triamine 
• 1361569-69-8 4-amino-6-ethyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pteridin-7(8H)-one 
• 1361569-68-7 4-amino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-propylpteridin-7(8H)-one 
• 1361569-58-5 4-amino-6-cyclopentyl-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pteridin-7(8H)-one 
• 1361569-57-4 4-amino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-(4-methylphenyl)pteridin-7(8H)-one 
• 1361569-62-1 4-amino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]-6-isopropylpteridin-7(8H)-one 

Relevant academic research and scientific papers

PROCESS FOR THE PREPARATION OF METHYL 4,6-DIAMINO-2-[1-(2-FLUOROBENZYL)-1H-PYRAZOLO[3,4-B]PYRIDIN-3-YL]-5-PYRIMIDINYL(METHYL)CARBAMATE AND ITS POLYMORPHS THEREOF

The present invention relates to an improved process for the preparation of methyl 4,6-diamino-2-[ 1-(2-fluorobenzyl)-1 H -pyrazolo[3,4-b )pyridin-3 -yl]-5-pyrimidinyl(methyl)carbamatecompound of formula-1 and its polymorphs thereof, represented by the fo

The preparation method of the west leo gua (by machine translation)

The invention discloses a method for preparation of west leo gua, its to 1 - (2 - fluorobenzyl) - 1 H - pyrazolo [3, 4 - b] pyridine - 3 - carboxamidine hydrochloride as the raw material, via the four-step reaction 2 - [1 - (2 - fluorobenzyl) - 1 H - pyra

PROCESS FOR THE PREPARATION OF METHYL 4,6-DIAMINO-2-[L-(2-FHIOROBENZVR)-LH-PYRAZOLO I3,4-BLPVRIDIN-3-VN-5-PYRIMIDINYL(METHVL)CARBAMATE AND ITS POLYMORPHS THEREOF

The present invention relates to process for the preparation of methyl 4,6-diamino-2-[1-(2-fluorobenzyl)-lH-pyrazolo[3,4-b]pyridin-3-yl]-5-pyrimidinyl(methyl)carbamate and its polymorphs thereof compound of formula-1, represented by the following structur

Discovery of the Soluble Guanylate Cyclase Stimulator Vericiguat (BAY 1021189) for the Treatment of Chronic Heart Failure

The first-in-class soluble guanylate cyclase (sGC) stimulator riociguat was recently introduced as a novel treatment option for pulmonary hypertension. Despite its outstanding pharmacological profile, application of riociguat in other cardiovascular indications is limited by its short half-life, necessitating a three times daily dosing regimen. In our efforts to further optimize the compound class, we have uncovered interesting structure-Activity relationships and were able to decrease oxidative metabolism significantly. These studies resulting in the discovery of once daily sGC stimulator vericiguat (compound 24, BAY 1021189), currently in phase 3 trials for chronic heart failure, are now reported.

Preparation method of riociguat

The invention discloses a preparation method of riociguat. The preparation method comprises the steps of firstly, taking 1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridine-3-formamidine hydrochloride and 2-aminopropanediamide as basic raw materials, adding str

A method for synthesizing [...]

The invention relates to a method for synthesizing riociguat. The method includes the following steps: 1, a compound 1-(2-fluorobenzyl)-1H-[3,4-b] pyridine derivative-3-formamidine hydrochloride (1) and a compound benzeneazomalononitrile (2) are reacted i

Preparation method and application of pyrazolo[3, 4-b]pyridine compound intermediate

The invention provides a preparation method and application of a pyrazolo[3, 4-b]pyridine compound intermediate. Specifically, the intermediate structure is shown as formula IV, wherein the groups are defined as the specification and claims. The intermedi

Method for compounding riociguat intermediate

The invention discloses a method for compounding riociguat intermediate, firstly 1-(2-fluorine benzyl) 1H-pyrazolo [3, 4-b] pyridine-3-formamidine hydrochloride are used as starting materials, and 2-[1-(2-fluorine benzyl)-1 H- pyrazolo [3, 4-b] pyridine-3-yl]-4, 5, 6-pyrimidine triamine of the riociguat intermediate are prepared by catalyzing and hydrogenating in normal pressure through a catalyst. The method for compounding the riociguat intermediate is mild in reaction conditions, prevents using a high pressure reaction kettle, reduces process demands to equipment, enables product purity to be bigger than 99.0% at last, and is suitable for commercial process.

PROCESS FOR PREPARING METHYL METHYLCARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND

The present invention relates to a process for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}methylcarbamate of the formula (I) and to a process for purifying the crude product of the compound of the for

PROCESS FOR PREPARING METHYL CARBAMATE AND ITS PURIFICATION FOR USE AS PHARMACEUTICALLY ACTIVE COMPOUND

The present invention relates to processes for preparing methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate, i.e. the compound of the formula (I) and to a process for purifying the crude product of the formul